ESMO 2018 | IMO-2125 plus ipilimumab for anti-PD-1 refractory melanoma: ILLUMINATE-301

Paolo Ascierto

Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, gives us an update on the ongoing Phase III ILLUMINATE-301 trial (NCT03445533) in anti-PD1 refractory melanoma, which is comparing the combination of the TLR9 agonist IMO-2125 with the CTLA-4 checkpoint inhibitor ipilimumab vs. ipilimumab alone.

Share this video